Source comparison
MOTS-c vs Tesofensine: Research Compound Comparison
Primary Mechanism Mitochondrial-to-nuclear retrograde signaling; activates AMPK and upregulates genes for insulin sensitivity and fatty acid oxidation Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin); blocks DAT, NET, SERT to prolong n
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Mitochondrial-to-nuclear retrograde signaling; activates AMPK and upregulates genes for insulin sensitivity and fatty acid oxidation
- Triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin); blocks DAT, NET, SERT to prolong neurotransmitter availability in CNS synapses
- MOTS-c targets cellular energy metabolism; Tesofensine targets brain appetite circuits. No mechanistic overlap
- Route of Administration
- Subcutaneous or intraperitoneal injection; requires reconstitution from lyophilized powder
- Oral administration; high bioavailability (~80%) as a lipophilic small molecule
- MOTS-c requires injection and cold storage; Tesofensine is orally bioavailable
- Half-Life
- Approximately 20–30 minutes in serum without modification
- 7–8 days; accumulates to steady state with repeated dosing
- MOTS-c requires daily dosing; Tesofensine allows once-weekly protocols
- Metabolic Effects
- Improves insulin sensitivity, glucose tolerance, mitochondrial biogenesis, and substrate flexibility independent of weight loss
- No direct metabolic benefit. Weight loss occurs solely via reduced caloric intake from appetite suppression
- MOTS-c improves how cells use energy; Tesofensine reduces energy intake
- Effect on Appetite
- No direct appetite suppression; does not cross blood-brain barrier in relevant concentrations
- Reduces ad libitum food intake by 20–30% in a dose-dependent manner through CNS mechanisms
- Tesofensine suppresses appetite; MOTS-c does not
- Cardiovascular Concerns
- Minimal; no sympathomimetic effects or cardiovascular stimulation reported in preclinical models
- Increases heart rate (7–10 bpm) and blood pressure (4–6 mmHg); requires cardiovascular monitoring
- MOTS-c has no cardiovascular risk; Tesofensine requires ECG and BP monitoring
- Research Context
- Studies on aging, insulin resistance, mitochondrial dysfunction, exercise metabolism, sarcopenia
- Obesity research, appetite regulation, reward circuitry dysfunction, binge eating models
- Choose based on whether the research question involves cellular metabolism (MOTS-c) or CNS appetite control (Tesofensine)